PIA
ACHN

Piedmont Investment Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Piedmont Investment Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,361
Closed -$7K – 2768
2018
Q2 		$7K Buy
+2,361
New +$8.04K ﹤0.01% 2007

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Piedmont Investment Advisors's ACHN Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q3 2018, closing a stake of 2,361 shares — an estimated $7K sold.

Piedmont Investment Advisors first reported a position in ACHN in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 137 funds tracked by Wall St. Rank hold ACHN as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Achillion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 2,361 Achillion Pharmaceuticals shares in Q3 2018, an estimated $7K.
  • Piedmont Investment Advisors first reported a position in Achillion Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Achillion Pharmaceuticals position peaked at $7K in Q2 2018.
  • 137 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.